DataMeds AI Unveils Galectovid for 2026 Cold & Flu Season
DataMeds AI, Inc. (NASDAQ:MEDS) has announced the U.S. direct-to-consumer launch of medical food Galectovid for the 2026 Cold & Flu Season through its #Back2School50% campaign.
Galectovid is a dietary management tool for galectin-1 and galectin-3 associated viral infections, targeting cellular viral invasion and host immune suppression. It is available over-the-counter without a prescription at partner Tollo Health's online store www.TolloHealth.Shop and at Corexa Pharmacy's online store http://www.corexarx.com/Store.
The effects of Galectovid are expected to begin within hours, according to the company. Galectovid is categorized as a medical food under section 5(b)(3) of the Orphan Drug Act (21 U.S.C. 360ee(b)(3)), with each of its ingredients on the U.S. Food & Drug Administration's Generally Recognized as Safe (GRAS) list.
'We believe that consumers will be extremely happy with Galectovid as their ally throughout the 2026 Cold & Flu Season,' said Gerald Commissiong, interim co-CEO of DataMEDS. 'We have begun expanding our Galectovid-focused acute infection research activities through key, pre-established, trusted physician relationships.'